CAR-M targeting CD19, CD22, HER-2, CD5, and carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) have been developed to fight against solid tumors and hematopoietic malignancies with improved tumor control and significant activation of TME [141–144]. The gene discussed is CD22; the disease is neoplasm.